Market analysis study carried out for the period of 2015-2027 shows that the Neuroblastoma Market will grow at the Compound Annual Growth Rate (CAGR) of 6.1% for the period (2015-2027).

New Delhi, India -- (SBWire) -- 08/16/2018 --Neuroblastoma originates in adrenal medulla and paraspinal or periaortic regions, where sympathetic nervous system tissue is present. It is the third most common childhood cancer, after leukemia and brain tumors, and is the most common solid extracranial tumor in children. Neuroblastoma is staged by the two systems that are INSS and INRGSS. Neuroblastoma cancer occurs most often in infants and young children, and is rarely found in children older than 10 years.

The male-to-female ratio observed in this disease for incidence cases is different, with males being affected more (country specific). Marginal male excess is a consistent finding throughout the geographies studied.

According to the latest report of DelveInsight, "Neuroblastoma- Market Insights, Epidemiology and Market Forecast-2027", In the United States, an estimated of around 23.5% of the total incident population of Neuroblastoma contributed to early stage (Stage I). In 7MM the incidence population of Neuroblastoma was 1,934 Cases in 2016. United States accounts for the highest NB Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. The region-wise market size for Neuroblastoma shows highest in US, followed by EU5, while Japan being the lowest, mainly due to lowest incident population for Neuroblastoma.

Unituxin, mAb therapy, was approved in the year 2015, while another therapy, Dinutuximab beta, was approved in 2017. Out of all the available treatment options Chemotherapy is still the only therapy which is applicable for all the stages. It is expected that with the new mAb Therapies, market (targeted) may shift towards Immunotherapy. Treatment regimens were dominated by injectable and intravenous therapies, but it is expected that oral therapies could take up some percent of share in the upcoming years. Omburtamab (BTD, ODD &RPDD), Naxitamab (ODD &RPDD) from Y-mAbs Therapeutics could create an impact in Neuroblastoma market.

The latest report has covered detailed description about available Treatment Algorithms. Complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Total market size of neuroblastoma with therapy specific market size is provided covering the 7MM to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the distribution of the given indication in 7MM. Complete market analysis with 2016 market size and 2027 market size is provided to understand the hidden growth potential in the market.
Request for sample pages:. https://www.delveinsight.com/report-store/neuroblastoma-market-insight-epidemiology-and-market-forecast

Reasons to buy:

-The report will help in developing business strategies by understanding trends shaping and driving the Neuroblastoma market.
-To understand the future market competition in the Neuroblastoma market and Insight reviews of the key market drivers and barriers.
-Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
-In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

- Cancer Prevention Pharmaceuticals
- MetronomX
- Genentech, Inc.
- Y-mAbs Therapeutics Inc.
- EUSA Pharma
- United Therapeutics Corp.
And many others……………..

Table of Contents:

1. Report Introduction
2. Neuroblastoma Market Overview at a Glance
2.1. Market Distribution of Neuroblastoma in 2016
2.2. Market Distribution of Neuroblastoma in 2027
2.3. Total Market by Region of Neuroblastoma (2016 & 2027)
3. Disease Background and Overview
4. Epidemiology and Patient Population
5. United States
5.1. Incident Population of Neuroblastoma
5.2. Distribution of Incident cases By Stage - Neuroblastoma
5.3. Treated Cases of Neuroblastoma
5.4. Treated Cases of Neuroblastoma by Therapy
6. EU5 countries
7. Germany
8. France
9. United Kingdom
10. Spain
11. Italy
12. Japan
13. Treatment Practices
14. Marketed Drugs
14.1. Unituxin: United Therapeutics Corp.
14.2. Dinutuximab Beta: EUSA Pharma
15. Phase III Drugs
15.1. Naxitamab: Y-mAbs Therapeutics Inc.
15.2. Omburtamab: Y-mAbs Therapeutics Inc.
16. Phase II Drugs
16.1. Bevacizumab+ Irinotecan +Temozolomide: Genentech, Inc.
16.2. MNX-100: MetronomX
16.3. CPP-1X: Cancer Prevention Pharmaceuticals
17. Neuroblastoma: Market Analysis
18. Market Outlook: 7Major Markets
19. Market size of Neuroblastoma in 7MM
20. Market Outlook: 7 Major Market
21. Neuroblastoma: US Market Outlook
21.1. US Market size
21.2. Neuroblastoma: EU5 Market Outlook
21.3. Germany Market size
21.4. France Market size
21.5. United Kingdom Market size
21.6. Spain Market size
21.7. Italy Market size
21.8. Neuroblastoma: Japan Market Outlook
21.9. Japan Market size
22. Appendix
23. Report Methodology
24. Consulting Services
25. Disclaimer

** This is not a detailed TOC.

Request for sample pages: https://www.delveinsight.com/report-store/neuroblastoma-market-insight-epidemiology-and-market-forecast

Related reports: https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight
https://www.delveinsight.com/report-store/neuroblastoma-epidemiology-forecast

About Delveinsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.